Dossier assessment

Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-141
Last updated

Report documents

  1. Extract of dossier assessment

    Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF document, 658 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-141_en
  2. Dossier assessment

    Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-141

Dossier assessment

Indication:

Adults with previously untreated diffuse large B-cell lymphoma

Result of dossier assessment:

Added benefit not proven

Press releases

Polatuzumab vedotin in untreated DLBCL: one step forward, two steps back

The manufacturer has designed its study for both the approval and Health Technology Assessments (HTA). However, the analyses planned for HTA were not submitted.

Additional information

Federal Joint Committee (G-BA)

2024-06-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-141
Commission
Commission awarded on 21.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-141_en

Connected Projects

  1. Dossier assessment

    Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G20-01
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G22-22
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-140
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form